Draft evidence report from the Institute for Clinical and Economic Review on the potentially curative rare disease treatment also supports the narrative that the unrestricted pricing environment in the US invites greater access to innovative treatments compared to markets abroad.
bluebird bio’s gene therapy for beta thalassemia, Zynteglo (betibeglogene autotemcel), would be cost effective at a price of $2.1m, especially if payments are spread over five years and based on outcomes, the Institute for Clinical and Economic Review tentatively concludes in a draft evidence report released 13 April.
“Despite remaining uncertainties, the evidence suggests that beti-cel provides net health benefits to patient with [transfusion dependent thalassemia] and given...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Industry says it is ready to work with the government on the recommendations from a major review of Australia’s health technology assessment system that covers areas such as discount rate reductions and setting up a separate budgetary allocation to temporarily subsidize access to certain drugs.
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
